Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases

NEW YORK--()--Bristol-Myers Squibb Company (NYSE:BMY) today announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases. Terms of the agreement were not disclosed.

The agreement supports Bristol-Myers Squibb’s long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs.

The innate immune system is the body’s first line of defense against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Contacts

Bristol-Myers Squibb
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Sarah Koenig, 609-252-4145
sarah.koenig@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com

Release Summary

Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune Diseases

Contacts

Bristol-Myers Squibb
Media:
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
Sarah Koenig, 609-252-4145
sarah.koenig@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com